Premium
Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma
Author(s) -
Kim Hee Kyung,
Oh Young Lyun,
Kim SeokHyung,
Lee Dong Youn,
Kang HoCheol,
Lee Ji In,
Jang Hye Won,
Hur Kyu Yeon,
Kim Jae Hyeon,
Min Yong Ki,
Chung Jae Hoon,
Kim Sun Wook
Publication year - 2012
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21716
Subject(s) - parathyroid carcinoma , immunohistochemistry , parathyroid adenoma , parathyroid neoplasm , staining , carcinoma , pathology , medicine , adenoma
Background Parafibromin is a protein encoded by the HRPT2 oncosuppressor gene, and the expression is reported to be decreased or absent in parathyroid carcinomas. Methods A total of 26 tumor specimens from 18 patients with adenoma and 8 patients with carcinoma were immune‐stained with an antibody against parafibromin. Results Parafibromin immunostaining showed strong positivity in 17 of 18 adenomas. Negative staining was noted in 3 of 8 carcinomas, and weak positivity was found in 3 of 8 carcinomas. The remaining 2 cases of carcinoma showed strong positivity. The loss of parafibromin expression (negative or weak positivity) demonstrated 94.4% specificity in the diagnosis of parathyroid carcinomas. Relapses or distant metastases of carcinoma occurred only in cases in which there was a loss of parafibromin immunostaining. Conclusions Loss of parafibromin immunostating showed promising results in the differential diagnosis of parathyroid carcinoma from adenoma and may also serve as a prognostic marker. © 2011 Wiley Periodicals, Inc. Head Neck, 2012